BGLAP and Osteopenia: In two double-blind, randomized clinical trials, Oligopin® showed beneficial effects in postmenopausal women with osteopenia, increasing bone formation markers and decreasing bone resorption (Majidi et al., 2021), as well as improving osteocalcin levels, the osteocalcin (OC)/type I collagen cross-linked C-telopeptide (CTX-1) ratio, oxidative stress, and antioxidant capacity (Panahande et al., 2019).